Study of CM512 Injection in Subjects With Moderate-to-severe Asthma

Summary

This study is a multicenter, randomized, double-blind, placebo-controlled phase II clinical trial evaluating the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of CM512 in subjects with moderate-to-severe asthma.

Timeline

Start

2025-08-19

Primary completion

2027-07-21

Completion

2027-07-21

Drugs

Indications